Search Results

You are looking at 181 - 190 of 4,064 items for :

  • Refine by Access: All x
Clear All
Full access

Quality Indicators in the Management of Bladder Cancer

Jeffrey S. Montgomery, David C. Miller, and Alon Z. Weizer

NCCN: Continuing Education Accreditation Statement This activity has been designated to meet the educational needs of physicians and nurses involved in the management of patients with cancer. There is no fee for this article. No commercial

Full access

Advocating for Equity in Cancer Care

James McCanney, Terrell Johnson, Lindsey A.M. Bandini, Shonta Chambers, Lynette Bonar, and Robert W. Carlson

How social determinants contribute to individual health and health equity has been the focus of recent research and increasing consensus. In cancer care, health outcomes are influenced by a variety of socioeconomic factors, including race

Full access

Central Nervous System Cancers

The University of Michigan Comprehensive Cancer Center

The incidence of primary malignant brain tumors is increasing, especially in the elderly, and metastatic disease to the central nervous system (CNS) occurs even more frequently (an incidence about 10 times that of primary brain tumors). In fact, estimates are that 20% to 40% of patients with systemic cancer will develop brain metastases. Primary and metastatic brain tumors are heterogeneous, with varied outcomes and management strategies. This marked heterogeneity means that prognostic features and treatment options must be carefully reviewed for each patient. As these guidelines note, the involvement of an interdisciplinary team is key in the appropriate management of these patients. Important updates to the guidelines include the addition of systemic chemotherapy as a salvage therapy treatment option for local recurrence and limited metastatic lesions and its deletion as an option for multiple metastatic lesions.

For the most recent version of the guidelines, please visit

Full access

The Economic Impact of Non-Melanoma Skin Cancer: A Review

Tejaswi Mudigonda, Daniel J. Pearce, Brad A. Yentzer, Phillip Williford, and Steven R. Feldman

N on-melanoma skin cancers (NMSCs), characterized by malignant growth of the epithelial layer or external surface of the skin, are the most prevalent form of skin cancer in the United States. 1 Since the 1960s, the incidence of NMSC has increased

Full access

Barriers to Clinical Trial Participation as Perceived by Oncologists and Patients

Neal J. Meropol, Joanne S. Buzaglo, Jennifer Millard, Nevena Damjanov, Suzanne M. Miller, Caroline Ridgway, Eric A. Ross, John D. Sprandio, and Perry Watts

This project was supported by the Pennsylvania Department of Health (ME# 02-285), the National Institutes of Health (R01 82085), and the Fox Chase Cancer Center Behavioral Research Core Facility and Population Studies Facility (P30CA06927

Full access

Involving Family and Social Support Systems in Tobacco Cessation Treatment for Patients With Cancer

The Cancer Center Cessation Initiative Family and Social Support Systems Working Group

Engaging Family and Social Support Systems in Tobacco Cessation in Cancer Care A cancer diagnosis and treatment are stressful life events, both physically and mentally. Social support provided by informal caregivers, family, and friends is

Full access

Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study

Firas Abdollah, Jesse D. Sammon, Kaustav Majumder, Gally Reznor, Giorgio Gandaglia, Akshay Sood, Nathanael Hevelone, Adam S. Kibel, Paul L. Nguyen, Toni K. Choueiri, Kathy J. Selvaggi, Mani Menon, and Quoc-Dien Trinh

Prostate cancer (PCa) is the most common noncutaneous cancer and the second leading cause of cancer-related death in North American men. 1 In the United States, 233,000 new cases of PCa are estimated to be diagnosed in 2014, along with 29,480 PCa

Full access

The Management of Patients With Stage IIIA Non–Small Cell Lung Cancer With N2 Mediastinal Node Involvement

Renato G. Martins, Thomas A. D’Amico, Billy W. Loo Jr, Mary Pinder-Schenck, Hossein Borghaei, Jamie E. Chaft, Apar Kishor P. Ganti, Feng-Ming (Spring) Kong, Mark G. Kris, Inga T. Lennes, and Douglas E. Wood

The management of patients with stage IIIA (N2) non–small cell lung cancer (NSCLC) remains the most challenging domain in thoracic oncology, and the use of evidence-based treatment guidelines is essential. 1 Notwithstanding improvements in the

Full access

Bladder Cancer

The UNMC Eppley Cancer Center at The Nebraska Medical Center

An estimated 61,420 new cases of urinary bladder cancer will be diagnosed in the United States in 2006, making it the fourth most common cancer in men and the ninth most common neoplasm in women. Because the median age of diagnosis is 65 years, medical comorbidities are a frequent consideration. The clinical spectrum of bladder cancer can be divided into 3 categories: noninvasive tumors, invasive lesions, and metastatic lesions. These categories differ in prognosis, management, and therapeutic goals, and these guidelines discuss management strategies to achieve the best possible outcomes.

For the most recent version of the guidelines, please visit

Full access

Impact of Incident Cancer on Short-Term Coronary Artery Disease–Related Healthcare Expenditures Among Medicare Beneficiaries

Ishveen Chopra, Malcolm D. Mattes, Patricia Findley, Xi Tan, Nilanjana Dwibedi, and Usha Sambamoorthi

may develop new conditions. The most common preexisting or existing conditions in patients with CAD include cancer, hypertension, diabetes, and other cardiovascular diseases. 5 For these individuals, CAD-related expenditures can be higher than for